FPAS
JAZZ icon

Focus Partners Advisor Solutions’s Jazz Pharmaceuticals JAZZ Stock Holding History

Focus Partners Advisor Solutions’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Sell
1,599
-627
-28% -$137K ﹤0.01% 910
2026
Q1 		$421K Buy
2,226
+705
+46% +$123K ﹤0.01% 853
2025
Q4 		$259K Buy
+1,521
New +$233K ﹤0.01% 932

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Focus Partners Advisor Solutions's JAZZ Position: Q2 2026 in Review

Focus Partners Advisor Solutions reduced its Jazz Pharmaceuticals (JAZZ) stake by 28% in Q2 2026, selling an estimated $137K and leaving 1,599 shares worth $385K. The position accounts for ﹤0.01% of the portfolio, ranked #910.

Focus Partners Advisor Solutions first reported a position in JAZZ in Q4 2025 and has held it in 3 quarters since. The position peaked at $421K in Q1 2026. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Focus Partners Advisor Solutions held 1,599 shares of Jazz Pharmaceuticals worth $385K as of Q2 2026.
  • Focus Partners Advisor Solutions sold 627 Jazz Pharmaceuticals shares in Q2 2026, an estimated $137K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #910 holding.
  • Focus Partners Advisor Solutions first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Focus Partners Advisor Solutions's Jazz Pharmaceuticals position peaked at $421K in Q1 2026.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.